Elizabeth "Nicki" Bush

Elizabeth (Nicki) Bush, an expert in measurement science and regulatory strategy, is Senior Director of Endpoints and Measurement Strategy at Johnson & Johnson Innovative Medicine and spent more than a decade at Eli Lilly and Company where she established and led the patient-focused endpoints and measurement center of expertise.

With more than 20 years of scientific and leadership experience, she continues to serve as an advisor within and outside of J&J, collaborating frequently with a diverse group of colleagues—including those from industry, patient advocacy groups, regulatory agencies, and academia. She recently completed a multi-year term as Industry Co-Director of Critical Path Institute’s PRO Consortium and currently co-leads an expert Task Force developing best research practices for assessment of performance-related outcomes in clinical trials. Always working to keep patients’ perspectives at the center of medical product development, Nicki has a knack for building diverse teams who thrive on advancing novel methods to do so. She has published and presented extensively on a range of topics related to patient-focused measurement and clinical outcome assessments.

Prior to working toward her PhD in Health and Behavior at the University of Maryland, Nicki earned her Master’s degree in Infectious Disease Epidemiology from Johns Hopkins University's Bloomberg School of Public Health and her BA in Philosophy and the History of Mathematics and Science from St. John’s College in Annapolis, MD. She grew up eating crabs in Maryland, but now lives just northwest of Indianapolis with her wife, their ten-year-old son, and two incredibly affectionate designer mutts: Archie Zipper and Murphy Button.